Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Revvity Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.4× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Revvity Inc pays a 0.18% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Revvity Inc for 12 Days on average.
| EMLC | RVTY | |
|---|---|---|
Market Cap | $4.93B | $16.98B |
Volume | 2,843,860 | 1,456,900 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $157.36 |
52-Week Low | $24.53 | $82.26 |
Typical Hold Time | 38 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.78, showing minimal daily change. The technical outlook is bearish, with moving averages and ADX signaling a downtrend, while oscillators are neutral. Recent news highlights the ETF hitting a 52-week low amid a strengthening U.S. dollar, which pressures emerging market local currency bonds. No fundamental financial ratios are available in the provided data, limiting traditional valuation analysis.
The outlook remains cautious due to macroeconomic headwinds like dollar strength and potential Fed rate hikes. Risks include currency volatility and rising bond yields. Analyst sentiment appears bearish, with the ETF facing challenges in the near term, though diversification benefits in foreign bonds may offer long-term value if conditions stabilize.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
